Epigenetics and Vasculitis: a Comprehensive Review

Clinical Reviews in Allergy and Immunology

Volumn 50, Issue 3, 2016, Pages 357-366

  Renauer, Paul ^a   Coit, Patrick ^a   Sawalha, Amr H ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NONE   (United States)

Author keywords

DNA methylation; Epigenetics; Histone modification; miRNA; Vasculitis

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA METHYLTRANSFERASE 1; GAMMA INTERFERON; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA 145; MICRORNA 155; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; HISTONE; IMMUNOGLOBULIN A; MICRORNA; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; BEHCET DISEASE; BINDING SITE; CPG ISLAND; CYTOKINE PRODUCTION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE LOCATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GIANT CELL ARTERITIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; IMMUNOPATHOGENESIS; LYMPHOCYTE DIFFERENTIATION; MUCOCUTANEOUS LYMPH NODE SYNDROME; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS; ANIMAL; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HISTONES; HUMANS; IMMUNOGLOBULIN A; MICRORNAS; SIGNAL TRANSDUCTION; VASCULITIS;

EID: 84931840932     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8495-6     Document Type: Review

References (91)

1. Jennette JC et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65(1):1–11
2. Hoffman GS, Calabrese LH (2014) Vasculitis: determinants of disease patterns. Nat Rev Rheumatol 10(8):454–62
3. Carmona FD, Martin J, Gonzalez-Gay MA (2015) Genetics of vasculitis. Curr Opin Rheumatol 27(1):10–7
4. Miller FW et al (2012) Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. J Autoimmun 39(4):259–71
5. Selmi C et al (2012) Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun 39(4):272–84
6. Stratta P et al (2001) The role of metals in autoimmune vasculitis: epidemiological and pathogenic study. Sci Total Environ 270(1–3):179–90
7. Lane SE et al (2003) Are environmental factors important in primary systemic vasculitis? A case–control study. Arthritis Rheum 48(3):814–23
8. Hogan SL et al (2007) Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case–control study. Clin J Am Soc Nephrol 2(2):290–9
9. Cartin-Ceba R, Peikert T, Specks U (2012) Pathogenesis of ANCA-associated vasculitis. Curr Rheumatol Rep 14(6):481–93
10. Lidar M et al (2012) Infectious serologies and autoantibodies in hepatitis C and autoimmune disease-associated mixed cryoglobulinemia. Clin Rev Allergy Immunol 42(2):238–46
11. Chimenti MS et al (2014) Vasculitides and the complement system: a comprehensive review. Clin Rev Allergy Immunol
12. Konstantinov KN, Ulff-Moller CJ, Tzamaloukas AH (2015) Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev 14(3):201–3
13. Wolffe AP, Matzke MA (1999) Epigenetics: regulation through repression. Science 286(5439):481–6
14. Lu Q (2013) The critical importance of epigenetics in autoimmunity. J Autoimmun 41:1–5
15. Lister R et al (2009) Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 462(7271):315–22
16. Renauer PA, Coit P, Sawalha AH (2015) The DNA methylation signature of human TCRalphabeta+CD4-CD8- double negative T cells reveals CG demethylation and a unique epigenetic architecture permissive to a broad stimulatory immune response. Clin Immunol 156(1):19–27
17. Balada E, Ordi-Ros J, Vilardell-Tarres M (2007) DNA methylation and systemic lupus erythematosus. Ann N Y Acad Sci 1108:127–36
18. Deaton AM, Bird A (2011) CpG islands and the regulation of transcription. Genes Dev 25(10):1010–22
19. Bird AP, Wolffe AP (1999) Methylation-induced repression—belts, braces, and chromatin. Cell 99(5):451–4
20. Surani MA (1998) Imprinting and the initiation of gene silencing in the germ line. Cell 93(3):309–12
21. Zhang Y et al (2013) Impaired DNA methylation and its mechanisms in CD4(+)T cells of systemic lupus erythematosus. J Autoimmun 41:92–9
22. Gupta B, Hawkins RD (2015) Epigenomics of autoimmune diseases. Immunol Cell Biol 93(3):271–6
23. Bhaumik SR, Smith E, Shilatifard A (2007) Covalent modifications of histones during development and disease pathogenesis. Nat Struct Mol Biol 14(11):1008–16
24. Kouzarides T (2007) Chromatin modifications and their function. Cell 128(4):693–705
25. Lee GR et al (2006) T helper cell differentiation: regulation by cis elements and epigenetics. Immunity 24(4):369–79
26. Liu Y et al (2013) Epigenetics in immune-mediated pulmonary diseases. Clin Rev Allergy Immunol 45(3):314–30
27. Deng X et al (2015) The role of microRNAs in autoimmune diseases with skin involvement. Scand J Immunol 81(3):153–65
28. Mello CC, Conte D Jr (2004) Revealing the world of RNA interference. Nature 431(7006):338–42
29. Fabian MR, Sonenberg N (2012) The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC. Nat Struct Mol Biol 19(6):586–93
30. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–97
31. Singh RP et al (2013) The role of miRNA in inflammation and autoimmunity. Autoimmun Rev 12(12):1160–5
32. Zeng L et al (2014) The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity 47(7):419–29
33. Hilhorst M et al (2015) Proteinase 3-ANCA vasculitis versus myeloperoxidase-ANCA vasculitis. J Am Soc Nephrol
34. Calafat J et al (1990) In situ localization by double-labeling immunoelectron microscopy of anti-neutrophil cytoplasmic autoantibodies in neutrophils and monocytes. Blood 75(1):242–50
35. van der Woude FJ et al (1985) Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1(8426):425–9
36. Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318(25):1651–7
37. Goeken JA (1991) Antineutrophil cytoplasmic antibody—a useful serological marker for vasculitis. J Clin Immunol 11(4):161–74
38. Cohen Tervaert JW, Damoiseaux J (2012) Antineutrophil cytoplasmic autoantibodies: how are they detected and what is their use for diagnosis, classification and follow-up? Clin Rev Allergy Immunol 43(3):211–9
39. Tervaert JW et al (1990) Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 33(8):1264–72
40. Falk RJ et al (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci U S A 87(11):4115–9
41. Little MA et al (2005) Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 106(6):2050–8
42. Xiao H et al (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110(7):955–63
43. Xiao H et al (2007) Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 170(1):52–64
44. Zeisberg M (2011) ANCA vasculitis meets epigenetics—closing in on the molecular roots of disease. Nephrol Dial Transplant 26(4):1146–8
45. Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89(10):3503–21
46. Cowland JB, Borregaard N (1999) The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules. J Leukoc Biol 66(6):989–95
47. Yang JJ et al (2004) Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. J Am Soc Nephrol 15(8):2103–14
48. Ciavatta DJ et al (2010) Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest 120(9):3209–19
49. Luo S et al (2013) Aberrant histone modifications in peripheral blood mononuclear cells from patients with Henoch–Schonlein purpura. Clin Immunol 146(3):165–75
50. Kuo HC et al (2015) Identification of an association between genomic hypomethylation of FCGR2A and susceptibility to Kawasaki disease and intravenous immunoglobulin resistance by DNA methylation array. Arthritis Rheumatol 67(3):828–36
51. Ryu J et al (2007) FcgammaRIIa mediates C-reactive protein-induced inflammatory responses of human vascular smooth muscle cells by activating NADPH oxidase 4. Cardiovasc Res 75(3):555–65
52. Hughes T et al (2014) Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behcet’s disease. Arthritis Rheumatol 66(6):1648–58
53. Coit P et al (2015) DNA methylation analysis of the temporal artery microenvironment in giant cell arteritis. Ann Rheum Dis. doi:10.1136/annrheumdis-2014-207116
54. Audemard-Verger A et al (2015) IgA vasculitis (Henoch–Shonlein purpura) in adults: diagnostic and therapeutic aspects. Autoimmun Rev 14(7):579–585
55. Ni FF et al (2014) Regulatory T cell microRNA expression changes in children with acute Kawasaki disease. Clin Exp Immunol 178(2):384–93
56. Guo MM et al (2015) Th17- and Treg-related cytokine and mRNA expression are associated with acute and resolving Kawasaki disease. Allergy 70(3):310–8
57. Shimizu C et al (2013) Differential expression of miR-145 in children with Kawasaki disease. PLoS One 8(3), e58159
58. Yun KW et al (2014) Elevated serum level of microRNA (miRNA)-200c and miRNA-371-5p in children with Kawasaki disease. Pediatr Cardiol 35(5):745–52
59. Magenta A et al (2011) miR-200c is upregulated by oxidative stress and induces endothelial cell apoptosis and senescence via ZEB1 inhibition. Cell Death Differ 18(10):1628–39
60. Li Y et al (2015) The SOX17/miR-371-5p/SOX2 axis inhibits EMT, stem cell properties and metastasis in colorectal cancer. Oncotarget 6(11):9099–112
61. Zhou Q et al (2012) Decreased microRNA-155 expression in ocular Behcet’s disease but not in Vogt Koyanagi Harada syndrome. Invest Ophthalmol Vis Sci 53(9):5665–74
62. Tang Y et al (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum 60(4):1065–75
63. Zhou Q et al (2014) MicroRNA-146a and Ets-1 gene polymorphisms in ocular Behcet’s disease and Vogt–Koyanagi–Harada syndrome. Ann Rheum Dis 73(1):170–6
64. Qi J et al (2013) A functional variant of pre-miRNA-196a2 confers risk for Behcet’s disease but not for Vogt–Koyanagi–Harada syndrome or AAU in ankylosing spondylitis. Hum Genet 132(12):1395–404
65. Yu H et al (2014) Predisposition to Behcet’s disease and VKH syndrome by genetic variants of miR-182. J Mol Med (Berl) 92(9):961–7
66. Stittrich AB et al (2010) The microRNA miR-182 is induced by IL-2 and promotes clonal expansion of activated helper T lymphocytes. Nat Immunol 11(11):1057–62
67. Ambrose NL, Haskard DO (2013) Differential diagnosis and management of Behcet syndrome. Nat Rev Rheumatol 9(2):79–89
68. Mat MC et al (2014) Behcet’s disease as a systemic disease. Clin Dermatol 32(3):435–42
69. Tulunay A et al (2015) Activation of the JAK/STAT pathway in Behcet’s disease. Genes Immun 16(2):170–5
70. Hirohata S (2008) Histopathology of central nervous system lesions in Behcet’s disease. J Neurol Sci 267(1–2):41–7
71. Direskeneli H, Fujita H, Akdis CA (2011) Regulation of TH17 and regulatory T cells in patients with Behcet disease. J Allergy Clin Immunol 128(3):665–6
72. Geri G et al (2011) Critical role of IL-21 in modulating TH17 and regulatory T cells in Behcet disease. J Allergy Clin Immunol 128(3):655–64
73. Aktas Cetin E et al (2014) IL-22-secreting Th22 and IFN-gamma-secreting Th17 cells in Behcet’s disease. Mod Rheumatol 24(5):802–7
74. Ceppi M et al (2009) MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. Proc Natl Acad Sci U S A 106(8):2735–40
75. O’Connell RM et al (2010) MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity 33(4):607–19
76. Hu R et al (2013) MicroRNA-155 confers encephalogenic potential to Th17 cells by promoting effector gene expression. J Immunol 190(12):5972–80
77. Yu Z et al (2007) Aberrant allele frequencies of the SNPs located in microRNA target sites are potentially associated with human cancers. Nucleic Acids Res 35(13):4535–41
78. Paine A et al (2010) Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol 80(12):1895–903
79. Gonzalez-Gay MA et al (2009) Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 61(10):1454–61
80. De Smit E, Palmer AJ, Hewitt AW (2015) Projected worldwide disease burden from giant cell arteritis by 2050. J Rheumatol 42(1):119–25
81. Djuretic IM et al (2007) Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat Immunol 8(2):145–53
82. Grewal IS, Flavell RA (1996) The role of CD40 ligand in costimulation and T-cell activation. Immunol Rev 153:85–106
83. Flanagan WM et al (1991) Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 352(6338):803–7
84. Schaufelberger C et al (2006) No additional steroid-sparing effect of cyclosporine A in giant cell arteritis. Scand J Rheumatol 35(4):327–9
85. Naesens M, Kuypers DR, Sarwal M (2009) Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4(2):481–508
86. Balakumar P et al (2014) Classical and pleiotropic actions of dipyridamole: not enough light to illuminate the dark tunnel? Pharmacol Res 87:144–50
87. Mulero MC et al (2009) Inhibiting the calcineurin-NFAT (nuclear factor of activated T cells) signaling pathway with a regulator of calcineurin-derived peptide without affecting general calcineurin phosphatase activity. J Biol Chem 284(14):9394–401
88. Kyttaris VC et al (2011) Calcium signaling in systemic lupus erythematosus T cells: a treatment target. Arthritis Rheum 63(7):2058–66
89. Feil R, Fraga MF (2011) Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 13(2):97–109
90. Weyand CM, Liao YJ, Goronzy JJ (2012) The immunopathology of giant cell arteritis: diagnostic and therapeutic implications. J Neuroophthalmol 32(3):259–65
91. Li Y et al (2010) Age-dependent decreases in DNA methyltransferase levels and low transmethylation micronutrient levels synergize to promote overexpression of genes implicated in autoimmunity and acute coronary syndromes. Exp Gerontol 45(4):312–22